Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amanda Maxwell

Managing Editor

London, UK

Amanda is EU medtech regulatory affairs editor at Medtech Insight. She has been reporting and providing analysis on developments in the field of medical technology regulatory affairs, with particular focus on the current and future EU regulations for medical devices, IVDs and device/drug combination products since the mid-1980s. She monitors and reports on all aspects of the implementation of the EU’s Medical Device and IVD Regulations, including relevant guidances, standards, expert opinions and ongoing challenges for all players in meeting the new requirements.

Her features have appeared in a variety of in-house publications and services. She also wrote medtech regulatory country profiles for Citeline’s former EU Law service and regularly contributes to In Vivo. Amanda regularly interviews experts in the EU medtech regulatory space and publishes interview podcasts. She also has experience in providing medtech regulatory strategy consultancy services, is often invited to speak and chair at EU meetings on medtech regulations and drug/device combination regulatory issues and is a frequent advisor to conference organizations.

Amanda enjoys taking part in LinkedIn discussions, has a background in the language and literature of Italy and France, and a passion for being part of the EU scene.

Latest From Amanda Maxwell

MDR Amending Regulation Officially Published And Already In Force

The deadlines for legacy products under the Medical Device Regulation have changed. Here are the essentials that all medtech players need to understand in how the MDR has now been amended.

EU Europe

Time For Talking: MedTech Europe Wants Clarity And Transparency Over MDR Amendment

The MDR amending regulation is on the cusp of being enforced. Most feel it is long overdue to prevent further medtech regulatory chaos in the EU. But the new text raises many questions itself. Medtech Insight spoke to MedTech Europe’s Petra Zoellner to understand what is needed next.

EU Europe

TEAM-NB Membership Increases By Over a Quarter Within Six Months

TEAM-NB was originally created to raise standards among notified bodies to an agreed harmonized level. Its latest expansion aims to continue that mission of spreading best conformity assessment practices.

Medical Device In Vitro Diagnostics

Official Sign-Off For EU Medical Device Regulation Amending Text Due Today

The first legal stages in the process for implementing new rules that will extend the Medical Device Regulation transitional period and remove the one-year sell-off period conditions are nearly complete. But further work will be needed.

Europe EU

Stack Of New And Revised EU MDR and IVDR Guidances In The Pipeline

The EU has published a lengthy list of new guidances to be drafted as well as existing guidance documents that need updating in the context of its MDR and IVD medtech regulations, including covering the interpretation of the Medical Device Regulation wording on “significant changes.”

Europe EU

France’s Snitem Demands Shock Cardiac Devices Reimbursement Decision Be Reversed

French medtech trade association, Snitem, and local cardiologists are stunned by the removal from the reimbursement list of two state-of-the art cardiology devices and are demanding their reinstatement.

Europe EU
See All
UsernamePublicRestriction

Register